For adults: Pfizer’s pneumonia vaccine approved
Prevenar 13 is indicated for adults 50 years of age and older for active immunisation.
NEW YORK:
Pfizer Inc has announced that the US Food and Drug Administration (FDA) has granted approval to the company’s pneumococcal conjugate vaccine Prevenar 13 as a single dose for use in adults. According to a press release, Prevenar 13 is indicated for adults 50 years of age and older for active immunisation for the prevention of pneumonia and invasive disease. “The approval of Prevenar 13 for adults offers the potential to contribute to the health of millions of aging Americans,” said Ian Read, Chairman and CEO of Pfizer Inc. In addition to the US, Pfizer has been granted approval for use of Prevenar 13 for various indications in adults in the European Union, Australia, Mexico and more than 10 other countries. Prevenar 13 was first approved in February 2010 for the prevention of invasive pneumococcal disease in infants and young children. PRESS RELEASE
Published in The Express Tribune, January 4th, 2012.
Pfizer Inc has announced that the US Food and Drug Administration (FDA) has granted approval to the company’s pneumococcal conjugate vaccine Prevenar 13 as a single dose for use in adults. According to a press release, Prevenar 13 is indicated for adults 50 years of age and older for active immunisation for the prevention of pneumonia and invasive disease. “The approval of Prevenar 13 for adults offers the potential to contribute to the health of millions of aging Americans,” said Ian Read, Chairman and CEO of Pfizer Inc. In addition to the US, Pfizer has been granted approval for use of Prevenar 13 for various indications in adults in the European Union, Australia, Mexico and more than 10 other countries. Prevenar 13 was first approved in February 2010 for the prevention of invasive pneumococcal disease in infants and young children. PRESS RELEASE
Published in The Express Tribune, January 4th, 2012.